An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016–present)
Sign Up to like & getrecommendations! Published in 2022 at "Expert Opinion on Therapeutic Patents"
DOI: 10.1080/13543776.2022.2132851
Abstract: ABSTRACT Introduction Rearranged during transfection (RET) is a transmembrane receptor tyrosine kinase. Aberrations in RET signaling due to mutations, gene fusions, or overexpression can lead to carcinomas. Six inhibitors have been approved for the treatment… read more here.
Keywords: kinase; ret inhibitors; ret; rearranged transfection ... See more keywords